CClinicalTrials.gg
Status unknownNCT04374643PsyConfPopUpdated Dec 29, 2020

Descriptive Study of the PSYchological Impact of CONFinement Measures in the General Population

An observational study in Depression and COVID 19, sponsored by University Hospital, Montpellier. Status unknown at 1 site in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-12-29.

Sponsored by University Hospital, Montpellier · Observational

The sponsor has not verified this record recently (last verified Dec 2020), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Ages
18 Years and older
Sex
All
01

Study summary

Quarantine is an unpleasant experience : separation from loved ones, loss of freedom, uncertainty about infection status, boredom. It may lead to negative mental health consequences and thus the emergence of anxiety and depressive symptoms.

From March 17th, 2020 to May 11th 2002, the French government has implemented national containment measures due to the Covid-19 epidemic.

Although there are data on the psychological impact and experience of quarantine measures in people who have been infected or suspected of being carriers of certain pathogens (e.g. Ebola), there are no data on such impact in the French population and quarantines lasting longer than 21 days. Investigators therefore propose to conduct a human and social sciences study in order to better understand the current situation

Read the detailed description

The main objective is to describe the psychological state during confinement (and the impact of the confinement) in a sample of the French general population.

Secondary objectives :

  • to assess the evolution of psychological health between the period of confinement and post-confinement.
  • to identify clinical factors modulating psychological state during confinement

It is expected to highlight :

  • a link between the intensity of anxiety symptoms and the number/quality of social contacts
  • a reduction of anxiety and depression symptoms in the post-confinement period.
  • higher consumption of drugs during the confinement period

Self-questionnaires (Google form format) are sent by mailing lists or social networks to participants in order to complete the assessment of psychological state. A unique identifier is sent in a separate email. These assessments are performed at least once during the confinement period. It is planned to repeat them when the confinement is lifted: 15 days, 3 and 6 months after the lifting of the confinement because of the risk of developing anxiodepressive symptoms, in particular post-traumatic stressors.

02

Conditions studied

  • Depression
  • COVID 19

Browse trials for

Keywords

  • Confinement
  • Depression
  • Post traumatic stress
  • Adults
03

In context

Depression

8,055 studies on the registry are indexed under Depression; 1,643 are open to participants now.

This study's planned enrollment of 500 is above the median of 160 across 1,084 observational studies indexed under Depression.

Browse Depression studies →

Lead sponsor

University Hospital, Montpellier is the lead sponsor of 1,244 studies on the registry; 225 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Adults who agree to participate by answering the questionnaires

Inclusion criteria

  • age> 18

Exclusion criteria

Exclusion criteria:

  • protective measure (curatorship, guardianship)
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (estimated)
Patient registry
No

Groups and cohorts

  • Confined patients

    General population

    Other: Slef questionnaires fulfilment

Interventions

  • OtherSlef questionnaires fulfilment

    Questionnaires to assess the psychological impact of confinement and its evolution over 6 months

06

What researchers measure

Primary outcomes

  1. Depressive Symptomatology

    depressive symptomatology with Patient Health Questionnaire : PHQ-9 scale (PHQ 9 higher score, more depressive -\> min : 0 max : 27)

    Time frame: during confinement

Secondary outcomes

  1. Depressive Symptomatology

    depressive symptomatology with Patient Health Questionnaire : PHQ-9 scale (PHQ 9 higher score, more depressive -\> min : 0 max : 27)

    Time frame: post-confinement : 15 days, 3 months, 6 months

Other outcomes

  1. Psychological pain

    Psychological pain : likert scale (higher score, more psychological pain-\> min : 0 max : 10)

    Time frame: during confinement

  2. sleep

    quality of sleep assessed with Insomnia Seveity Index (ISI Insomnia Severity Scale ; higher score, more insomnia -\> min : 0 max : 28)

    Time frame: during confinement

  3. sleep

    quality of sleep assessed with Insomnia Seveity Index (ISI Insomnia Severity Scale ; higher score, more insomnia -\> min : 0 max : 28)

    Time frame: post-confinement (15 days, 3 months, 6 months)

  4. anxiety

    anxiety intensity assessed by Generalized Anxieety Disorder (GAD 7 Generalized Anxiety Disorder higher score, more anxious -\> min : 0 max : 21)

    Time frame: during confinement

  5. anxiety

    anxiety intensity assessed by Generalized Anxieety Disorder (GAD 7 Generalized Anxiety Disorder higher score, more anxious -\> min : 0 max : 21)

    Time frame: post-confinement (15 days, 3 months, 6 months)

  6. psychological pain

    psychological pain : likert scale (higher score, more psychological pain-\> min : 0 max : 10)

    Time frame: post-confinement (15 days, 3 months, 6 months)

  7. physical pain

    psychological pain : likert scale (higher score, more psychological pain-\> min : 0 max : 10)

    Time frame: during confinement

  8. physical pain

    psychological pain : likert scale higher score, more psychological pain-\> min : 0 max : 10)

    Time frame: post-confinement (15 days, 3 months, 6 months)

  9. anger

    staxi state scale (STAXI ; State and Trait Anger Expression Inventory : higher score, more anger -\> min : 0 max : 50)

    Time frame: during confinement

  10. anger

    staxi state scale (STAXI ; State and Trait Anger Expression Inventory : higher score, more anger -\> min : 0 max : 50)

    Time frame: post-confinement (15 days, 3 months, 6 months)

  11. Stressful Event Impact

    Assessed by the Stressful Event Impact Scale - Horowitz (HOROWITZ higher score, more traumatizes -\> min : 0 max : 45) )

    Time frame: during confinement

  12. Stressful Event Impact

    Assessed by the Stressful Event Impact Scale - Horowitz (HOROWITZ higher score, more traumatizes -\> min : 0 max : 45)

    Time frame: post-confinement (15 days, 3 months, 6 months)

  13. Use of psychotropic drugs

    Number of patients declaring an increase of psychotropic drug use

    Time frame: during confinement

  14. Use of psychotropic drugs

    Number of patients declaring an increase of psychotropic drug use

    Time frame: post-confinement (15 days, 3 months, 6 months)

  15. Tobacco consumption

    Number of patients declaring an increase of tobacco consumption

    Time frame: during confinement

  16. Tobacco consumption

    Number of patients declaring an increase of tobacco consumption

    Time frame: post-confinement (15 days, 3 months, 6 months)

  17. alcohol consumption

    Number of patients declaring an increase of alcohol consumption

    Time frame: post-confinement (15 days, 3 months, 6 months)

  18. alcohol consumption

    Number of patients declaring an increase of alcohol consumption

    Time frame: confinement

  19. Illicit substances consumption

    Number of patients declaring an increase of illicit substances consumption

    Time frame: confinement

  20. Illicit substances consumption

    Number of patients declaring an increase of illicit substances consumption

    Time frame: post-confinement (15 days, 3 months, 6 months)

  21. orientation of life

    Life Orinetation Test Revised (LOT-R questionnaire): higher score, more optimistic --\> min : 0 max : 24

    Time frame: confinement

  22. orientation of life

    Life Orinetation Test Revised (LOT-R questionnaire): higher score, more optimistic --\> min : 0 max : 24

    Time frame: post-confinement (15 days, 3 months, 6 months)

07

Study locations

1 of 1 sites recruiting
  • University hospital
    Montpellier, 34295, France
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — NC

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 29, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04374643
Lead sponsor
University Hospital, Montpellier
Responsible party
Sponsor
First posted
May 5, 2020
Start date
Apr 1, 2020
Primary completion
Dec 1, 2021 (estimated)
Completion
Dec 30, 2021 (estimated)
Last update
Dec 29, 2020

Study contacts

Emilie Olie, MD PhD
Contact
e-olie@chu-montpellier.fr
+33 4 67 33 85 81
Emilie Olie, MD PhD
principal investigator · University Hospital, Montpellier

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion